Cellectis S.A.
$2.47▼ 1.59%($-0.04)
TickerSpark Score
51/100
▌ Mixed
65
Valuation
40
Profitability
55
Growth
64
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALCLS.PA research report →
52-Week Range34% of range
Low
$1.25
Current
$2.47
High
$4.84
Company Overviewwww.cellectis.com
About the company
Cellectis S. A. , a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology.
- CEO
- Andre Choulika
- IPO
- 2007
- Employees
- 216
- HQ
- Paris, FR
Price Chart
+92.97% · this period
Valuation
- Market Cap
- $178.50M
- P/E
- -4.16
- P/S
- 2.98
- P/B
- 4.71
- EV/EBITDA
- -6.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.86%
- Op Margin
- -69.23%
- Net Margin
- -98.69%
- ROE
- -80.61%
- ROIC
- -27.24%
Growth & Income
- Revenue
- $75.92M · 82.92%
- Net Income
- $-70,348,761 · -91.37%
- EPS
- $-0.70 · -70.73%
- Op Income
- $-42,003,392
- FCF YoY
- -330.34%
Performance & Tape
- 52W High
- $4.84
- 52W Low
- $1.25
- 50D MA
- $3.13
- 200D MA
- $3.36
- Beta
- 2.75
- Avg Volume
- 318.37K
Get TickerSpark's AI analysis on ALCLS.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · ALCLS.PA
Our ALCLS.PA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on ALCLS.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALCLS.PA report →Internal Compare
Similar companies
Peers in the same neighborhood.